Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FindMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI:

The FindMNDBiomarker Program: Protein Changes in Motor Neuron Disease/Amyotrophic Lateral Sclerosis Postmortem Tissue and Biofluids 

DOI: https://doi.org/10.1002/ana.27300

Contact: For help contact [email protected]

Sort by:
Total Records Found: 4574, showing 100 per page
Biomarker NameUniProt IDPublicationDisease GroupComparator GroupSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
GPC4 O75487 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GPC1 P35052 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
GP1BA P07359 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GP1BA P07359 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
GOT2 P00505 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GOT2 P00505 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GOT2 P00505 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
GOT2 P00505 Zubiri et al. 2018 ALS fast (early stage) ALS slow (early stage) Plasma Down 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
GOT2 P00505 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
GOT2 P00505 Zubiri et al. 2018 Late ALS (ALS fast cohort) Early ALS (ALS fast cohort) Plasma Down 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
GOT2 P00505 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
GOT1 P17174 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
GOT1 P17174 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
GOT1 P17174 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GOT1 P17174 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
GOT1 P17174 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GOLM1 Q8NBJ4 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
GNRH1 P01148 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GNPTG Q9UJJ9 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
GNPDA2 Q8TDQ7 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GNG7 O60262 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GNG5 P63218 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GNG3 P63215 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
GNB1 P62873 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
GNAZ P19086 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
GNAS O95467 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
GNAO1 P09471 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GNAI2 P04899 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GNAI2 P04899 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
GMPPB Q9Y5P6 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
GMFG M0QYG8 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
GMFB G3V4P8 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
GMFB P60983 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GM2A P17900 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
GM2A P17900 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GLUD1 P00367 Filareti et al. 2017 Late ALS Early ALS PBMCs Up 16 Early-ALS, 16 Late-ALS N/A 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS) N/A
GLTP Q9NZD2 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GLS O94925 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
GLRX P35754 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GLOD4 Q9HC38 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
GLOD4 Q9HC38 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GLOD4 Q9HC38 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
GLOD4 Q9HC38 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
GLO1 Q04760 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
GLO1 Q04760 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GLO1 Q04760 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
GLO1 Q04760 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
GLO1 Q04760 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GLG1 Q92896 Trautwig et al. 2025 Sporadic ALS Control CSF Down 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
GLG1 Q92896 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
GLG1 Q92896 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
GLDN Q6ZMI3 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
GLDN Q6ZMI3 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
GLDN Q6ZMI3 Zhou et al. 2023 BO-ALS SO-ALS CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
GJA9 P57773 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
GIT1 A0A0C4DGN6 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
GINM1 Q9NU53 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
GIMAP4 C9IZQ3 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
GHR P10912 Berrone et al. 2023 ALS Control Plasma Down 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
GHR P10912 Berrone et al. 2023 sALS Control Plasma Down 8 sALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
GGT7 Q9UJ14 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
GGT7 Q9UJ14 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
GGT7 Q9UJ14 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
GGT7 Q9UJ14 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
GGT5 P36269 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
GGT5 P36269 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GGT5 P36269 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
GGT1 P19440 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
GGCT O75223 Englen-Lee et al. 2017 ALS Control Spinal cord (PH & AH) Up 10 ALS, 10 control 57.6 ± 10.9 62.6 ± 10.6 N/A
GFRA3 O60609 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GFRA3 O60609 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
GFRA2 O00451 Vu et al. 2023 ALS fast ALS slow CSF Down 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
GFRA1 P56159 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
GFAP P14136 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
GET4 C9JPA8 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
GELS P06396 Vilardo et al. 2024 ALS (discovery cohort) Control (discovery cohort) Plasma EVs Down 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
GDI2 P50395 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
GDI2 P50395 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GDI2 P50395 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
GDI1 P31150 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GDI1 P31150 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
GDI1 P31150 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
GDF11 O95390 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
GDF10 P55107 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
GDF10 P55107 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
GDAP1L1 Q96MZ0 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
GDA Q9Y2T3 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
GC D6RF35 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GC P02774 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
GBP1 P32455 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
GBA P04062 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
GBA P04062 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
GATD3B A0A0B4J2D5 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
GAS2 O43903 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
GAPDH P04406 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GAPDH P04406 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
GAPDH P04406 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
GAPDH P04406 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
GAP43 P17677 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
GAP43 P17677 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A